Cancer Genetics to Evaluate Biomarkers for Effector Therapeutics – GenomeWeb

NEW YORK (GenomeWeb) Cancer Genetics said today that it has been hired by Effector Therapeutics to provide clinical biomarker services for Effector's lead product candidate, eFT508 a highly selective oral small molecule inhibitor of MNK1 and MNK2.

Registering provides access to this and other free content.

Already have an account? .

Read the original:
Cancer Genetics to Evaluate Biomarkers for Effector Therapeutics - GenomeWeb

Related Posts